What is Livagen?

A synthetic four-amino-acid peptide (Lys-Glu-Asp-Ala) studied in laboratory models of chromatin, protein synthesis and digestive-enzyme activity.

Livagen in the library · Bioregulator Peptides · Human Trials · What are peptides?

0 registered trials · 0 indexed papers · 13 human / 5 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Livagen is described as a synthetic four-amino-acid peptide studied mainly in laboratory models of chromatin, protein synthesis and digestive-enzyme activity. Published studies identify it as Lys-Glu-Asp-Ala (KEDA), from the short-peptide bioregulator research program associated with Vladimir Khavinson and collaborators.

It is often called a liver peptide, a label described as not being evidence for fatty liver, hepatitis or age-related liver disease. Some experiments used cells from older people outside the body; they did not give Livagen to older adults.

More cited research

Related compounds

FAQ

What is Livagen?

A synthetic four-amino-acid peptide (Lys-Glu-Asp-Ala) studied in laboratory models of chromatin, protein synthesis and digestive-enzyme activity.

How many registered human trials study Livagen?

The PeptideWhiz trial index lists 0 registered trials for Livagen.

How much published research exists on Livagen?

By study type, PeptideWhiz counts 13 human and 5 animal studies on Livagen.

Which conditions is Livagen researched for?

No condition pages are linked to this compound yet.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).